Sonoma Pharmaceuticals, Inc. (SNOA)

Sonoma Pharmaceuticals' stock price has declined significantly in the past six months. On April 30, 2026, the company closed a $4 million stock and warrant sale. On April 27, 2026, a 2.96 million-unit offering priced at $1.35 per unit led to a -36.67% single-day stock decline. On February 10, 2026, Sonoma Pharmaceuticals reported its third fiscal quarter 2026 financial results, with a GAAP EPS of -$0.48 and revenue of $4.3 million, missing consensus estimates. On November 4, 2025, the company reported its second fiscal quarter 2026 financial results, showing record quarterly revenue of $5.6 million, a 57% increase year-over-year.

While specific information on demand seasonality is limited, historical stock performance suggests some seasonality, with May showing a tendency for a "green month" in terms of stock performance.

Sonoma Pharmaceuticals, Inc. specializes in stabilized hypochlorous acid (HOCl) products using its patented Microcyn® technology, addressing chronic and acute conditions. Its product portfolio includes wound care, animal health care, eye care, oral care, nasal care, podiatry, and dermatological applications, available as prescription, OTC, and office-dispense products. Key products include dermatology solutions like Epicyn and Levicyn, wound care products such as Microcyn, animal health care solutions like MicrocynAH, eye care products like Ocucyn, oral and nasal care products like Microdacyn60, and disinfectants like Nanocyn.

Sonoma Pharmaceuticals has a global presence, selling products directly or through partners in over 55 countries, including the United States, Latin America, Europe, and Asia. The company's principal office is in Boulder, Colorado, with manufacturing in Guadalajara, Mexico, and European marketing and sales in Roermond, Netherlands.

Sonoma Pharmaceuticals has enhanced its brand reputation through several positive developments. Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel received the National Rosacea Society Seal of Acceptance. The company expanded its market reach by registering its manufacturing facility and listing its Microcyn-based facial spray under the FDA's MoCRA. Sonoma Pharmaceuticals announced the U.S. retail launch of its advanced burn relief hydrogel in CVS and Walmart. The company launched a new dermatology product line, Aquanil AD, for sensitive skin under Person & Covey's Aquanil Brand for U.S. over-the-counter distribution. Sonoma Pharmaceuticals and Medline Industries launched a new HOCl Wound Cleanser for U.S. Hospitals.

Sonoma Pharmaceuticals has a mixed ownership structure. Institutional investors hold approximately 1.95% to 7.13% of the company's stock. Insiders own approximately 29.35% of the stock, while public companies and individual investors hold about 63.52%. Bruce Thornton owns the most shares of Sonoma Pharmaceuticals.